China Universal Asset Management Company’s Tarsus Pharmaceuticals TARS Stock Holding History

China Universal Asset Management Company’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$530K	Buy	7,552 +635	+9%	+$44.4K	0.04%	250
2025 Q4	$566K	Sell	6,917 -483	-7%	-$36.1K	0.04%	248
2025 Q3	$440K	Sell	7,400 -1,038	-12%	-$51.1K	0.04%	260
2025 Q2	$342K	Buy	8,438 +740	+10%	+$33.3K	0.03%	275
2025 Q1	$395K	Sell	7,698 -408	-5%	-$20.2K	0.04%	264
2024 Q4	$449K	Buy	8,106 +789	+11%	+$35.8K	0.04%	260
2024 Q3	$241K	Buy	7,317 +2,879	+65%	+$80.9K	0.03%	283
2024 Q2	$121K	Sell	4,438 -2,129	-32%	-$71.6K	0.02%	290
2024 Q1	$239K	Buy	6,567 +2,735	+71%	+$80.4K	0.03%	271
2023 Q4	$77.6K	Buy	3,832 +3,004	+363%	+$50.2K	0.02%	315
2023 Q3	$14.7K	Buy	828 +476	+135%	+$8.42K	﹤0.01%	319
2023 Q2	$6.36K	Sell	352 -10	-3%	-$159	﹤0.01%	347
2023 Q1	$4.55K	Buy	362 +91	+34%	+$1.33K	﹤0.01%	373
2022 Q4	$3.97K	Buy	+271	New	+$4.48K	﹤0.01%	321

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

China Universal Asset Management Company's TARS Position: Q1 2026 in Review

China Universal Asset Management Company increased its Tarsus Pharmaceuticals (TARS) stake by 9.2% in Q1 2026, buying an estimated $44.4K and bringing the position to 7,552 shares worth $530K. The position accounts for 0.04% of the portfolio, ranked #250.

China Universal Asset Management Company first reported a position in TARS in Q4 2022 and has held it in 14 quarters since. The position peaked at $566K in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

China Universal Asset Management Company held 7,552 shares of Tarsus Pharmaceuticals worth $530K as of Q1 2026.
China Universal Asset Management Company bought 635 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $44.4K.
Tarsus Pharmaceuticals made up 0.04% of China Universal Asset Management Company's portfolio in Q1 2026, its #250 holding.
China Universal Asset Management Company first reported a position in Tarsus Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
China Universal Asset Management Company's Tarsus Pharmaceuticals position peaked at $566K in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.